Trial of Dronabinol and Vaporized Cannabis in Neuropathic Low Back Pain
Status:
Completed
Trial end date:
2020-03-25
Target enrollment:
Participant gender:
Summary
This study will involve treating low back pain associated with nerve injury with oral
delta-9-tetrahydrocannabinol (Δ9-THC) or whole plant cannabis for eight weeks. Research
subjects will consume either oral Δ9-THC (dronabinol), vaporized 3.7% Δ9-THC/5.6% CBD, or
placebo. An analysis will then be determined to assess the risk--benefit ratio of dronabinol
and vaporized 3.7% Δ9-THC/5.6% CBD .